Roberto J. Firpi, Manal F. Abdelmalek, Consuelo Soldevila‐Pico, Roniel Cabrera, Jonathan J. Shuster, Douglas Theriaque, Alan I. Reed, Alan W. Hemming, Chen Liu, James M. Crawford, David R. Nelson – 16 September 2004 – Determinants of progression to cirrhosis in hepatitis C virus (HCV) infection have been well described in the immunocompetent population but remain poorly defined in liver transplant (LT) recipients. This cohort study determines the factors contributing to the development of fibrosis and its rate of progression in the allograft.

Suzanne Norris, Chris Taylor, Paolo Muiesan, Bernard C. Portmann, Alex S. Knisely, Matthew Bowles, Mohamed Rela, Nigel Heaton, John G. O'Grady – 16 September 2004 – Liver transplantation (LT) in human immunodeficiency virus (HIV)‐positive individuals is considered to be an experimental therapy with limited reported worldwide experience, and little long‐term survival data. Published data suggest that the short‐term outcome is encouraging in selected patients.

Mitchell L. Shiffman, R. Todd Stravitz, Melissa J. Contos, A. Scott Mills, Richard K. Sterling, Velimir A. Luketic, Arun J. Sanyal, Adrian Cotterell, Daniel Maluf, Marc P. Posner, Robert A. Fisher – 16 September 2004 – Hepatitis C virus (HCV) recurs in nearly all patients after liver transplantation. This recurrence is associated with progressive fibrosis and graft loss. It remains unclear whether the natural course of HCV recurrence is altered in patients who undergo living donor liver transplantation (LDLT).

Robert S. Brown – 16 September 2004

Charles Miller, Sander Florman, Leona Kim‐Schluger, Patrick Lento, Julia De La Garza, Josephine Wu, Boxun Xie, Wandi Zhang, Edward Bottone, David Zhang, Myron Schwartz – 16 September 2004 – A 57‐year‐old male with a history of hypercholesterolemia and anxiety but otherwise in good health volunteered to donate the right lobe of his liver to his brother. The operation was performed uneventfully, without transfusion. Postoperatively he did well, until he developed tachycardia, profound hypotension, and coffee ground emesis on postoperative day 3.

Srikanth Reddy, Miguel Zilvetti, Jens Brockmann, Andrew McLaren, Peter Friend – 16 September 2004 – Liver transplantation is the treatment of choice for many patients with acute and chronic liver failure, but its application is limited by a shortage of donor organs. Donor organ shortage is the principal cause of increasing waiting lists, and a number of patients die while awaiting transplantation. Non–heart‐beating donor (NHBD) livers are a potential means of expanding the donor pool. This is not a new concept.

Brendan C. Visser, Insoo Suh, Shinjiro Hirose, Philip Rosenthal, Hanmin Lee, John P. Roberts, Ryutaro Hirose – 16 September 2004 – After portoenterostomy (PE) for biliary atresia (BA), many patients suffer progressive deterioration of liver function and ultimately require liver transplantation. We retrospectively reviewed a single center's experience with pediatric liver transplantation for BA from 1988 to 2002. Sixty‐six patients underwent 69 liver transplants for BA.

Robert A. Fisher – 16 September 2004

Paul J. Thuluvath, Hwan Y. Yoo – 16 September 2004 – Live donor liver transplantation (LDLT) has become increasingly common in the United States and around the world. In this study, we compared the outcome of 764 patients who received LDLT in the United States and compared the results with a matched population that received deceased donor transplantation (DDLT) using the United Network for Organ Sharing (UNOS) database.

Margarita Sala, Josep Fuster, Josep M. Llovet, Miquel Navasa, Manel Solé, María Varela, Fernando Pons, Antoni Rimola, Juan Carlos García‐Valdecasas, Concepció Brú, Jordi Bruix – 16 September 2004 – Surgical resection and liver transplantation offer a 5‐year survival greater than 70% in patients with hepatocellular carcinoma, but the high recurrence rate impairs long‐term outcome after resection. Pathological data such as vascular invasion and detection of additional nodules predict recurrence and divide patients into high and low risk profile.